Kyntra Bio (NASDAQ:KYNB) Lowered to “Sell” Rating by Wall Street Zen

Kyntra Bio (NASDAQ:KYNB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other research firms also recently weighed in on KYNB. HC Wainwright upgraded Kyntra Bio to a “strong-buy” rating in a research note on Friday, February 27th. Zacks Research cut Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, Weiss Ratings assumed coverage on Kyntra Bio in a report on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kyntra Bio presently has an average rating of “Hold”.

Kyntra Bio Stock Down 2.3%

Shares of NASDAQ KYNB opened at $7.13 on Friday. Kyntra Bio has a fifty-two week low of $4.85 and a fifty-two week high of $12.60. The firm’s 50 day simple moving average is $7.74. The company has a market capitalization of $28.88 million, a P/E ratio of 0.16 and a beta of 0.84.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.